Literature DB >> 26773814

Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.

Yok-Lam Kwong1, David Lopes2, Pek-Lan Khong3.   

Abstract

Entities:  

Keywords:  PD-1; hodgkin lymphoma; pembrolizumab; refractory

Mesh：

Substances：

Year:  2016        PMID： 26773814     DOI： 10.1111/bjh.13920

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Pembrolizumab (Keytruda).

Authors:  Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

Review 2.  Pembrolizumab in classical Hodgkin's lymphoma.

Authors:  Joseph Maly; Lapo Alinari
Journal:  Eur J Haematol       Date:  2016-05-30       Impact factor: 2.997

3.  A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin.

Authors:  Peipei Xu; Fan Wang; Chaoyang Guan; Jian Ouyang; Xiaoyan Shao; Bing Chen
Journal:  Onco Targets Ther       Date:  2016-09-21       Impact factor: 4.147

Review 4.  Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.

Authors:  Magdalena Witkowska; Piotr Smolewski
Journal:  J Immunol Res       Date:  2018-04-11       Impact factor: 4.818

5.  Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

Authors:  Rong Tao; Lei Fan; Yongping Song; Yu Hu; Wei Zhang; Yafei Wang; Wei Xu; Jianyong Li
Journal:  Signal Transduct Target Ther       Date:  2021-10-27

Review 6.  Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.

Authors:  Mengjie Jiang; Yujie Hu; Gang Lin; Chao Chen
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

7.  Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.

Authors:  Wen-Chun Chen; Pen-Yuan Chu; Yu-Ting Lee; Wen-Bin Lu; Chun-Yu Liu; Peter Mu-Hsin Chang; Muh-Hwa Yang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

Review 8.  Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.

Authors:  José R Cortés; Teresa Palomero
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.